Personalis, Inc. Cost of Revenue
Personalis, Inc. (PSNL) reported Cost of Revenue of $17.61 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-04
- Personalis, Inc. cost of revenue for the quarter ending 2026-06-30 was $17.61M, a 41.51% increase year-over-year.
- Personalis, Inc. cost of revenue for the quarter ending 2026-03-31 was $15.19M, a 13.38% increase year-over-year.
- Personalis, Inc. cost of revenue for the quarter ending 2025-12-31 was $15.45M, a 26.08% increase year-over-year.
- Personalis, Inc. cost of revenue for the quarter ending 2025-09-30 was $12.58M, a 25.84% decline year-over-year.
- Personalis, Inc. cost of revenue for fiscal 2025 was $53.87M, a 6.78% decline from fiscal 2024.
- Personalis, Inc. cost of revenue for fiscal 2024 was $57.79M, a 4.55% increase from fiscal 2023.
- Personalis, Inc. cost of revenue for fiscal 2023 was $55.27M, a 6.92% increase from fiscal 2022.
- Personalis, Inc. cost of revenue for fiscal 2022 was $51.70M, a 3.97% decline from fiscal 2021.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.61M 10-Q · filed 2026-08-04 | $32.80M 10-Q · filed 2026-08-04 | $48.25M derived: sum of 3 quarters · filed 2026-08-04 | $60.83M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $15.19M 10-Q · filed 2026-05-07 | $30.64M derived: sum of 2 quarters · filed 2026-05-07 | $43.22M derived: sum of 3 quarters · filed 2026-05-07 | $55.66M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $15.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $28.03M derived: sum of 2 quarters · filed 2026-02-26 | $40.47M derived: sum of 3 quarters · filed 2026-08-04 | $53.87M 10-K · filed 2026-02-26 |
| 2025-09-30 | $12.58M 10-Q · filed 2025-11-04 | $25.03M derived: sum of 2 quarters · filed 2026-08-04 | $38.43M 10-Q · filed 2025-11-04 | $50.68M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $12.45M 10-Q · filed 2026-08-04 | $25.84M 10-Q · filed 2026-08-04 | $38.09M derived: sum of 3 quarters · filed 2026-08-04 | $55.06M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $13.40M 10-Q · filed 2026-05-07 | $25.65M derived: sum of 2 quarters · filed 2026-05-07 | $42.61M derived: sum of 3 quarters · filed 2026-05-07 | $57.16M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $12.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $29.21M derived: sum of 2 quarters · filed 2026-02-26 | $43.76M derived: sum of 3 quarters · filed 2026-02-26 | $57.79M 10-K · filed 2026-02-26 |
| 2024-09-30 | $16.96M 10-Q · filed 2025-11-04 | $31.51M derived: sum of 2 quarters · filed 2025-11-04 | $45.54M 10-Q · filed 2025-11-04 | $60.01M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $14.54M 10-Q · filed 2025-08-05 | $28.57M 10-Q · filed 2025-08-05 | $43.05M derived: sum of 3 quarters · filed 2025-08-05 | $57.81M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $14.03M 10-Q · filed 2025-05-06 | $28.50M derived: sum of 2 quarters · filed 2025-05-06 | $43.27M derived: sum of 3 quarters · filed 2025-05-06 | $55.17M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $14.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $29.24M derived: sum of 2 quarters · filed 2025-02-27 | $41.14M derived: sum of 3 quarters · filed 2025-02-27 | $55.27M 10-K · filed 2025-02-27 |
| 2023-09-30 | $14.77M 10-Q · filed 2024-11-06 | $26.67M derived: sum of 2 quarters · filed 2024-11-06 | $40.80M 10-Q · filed 2024-11-06 | $55.21M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $11.91M 10-Q · filed 2024-08-07 | $26.04M 10-Q · filed 2024-08-07 | $40.45M derived: sum of 3 quarters · filed 2024-08-07 | $52.83M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $14.13M 10-Q · filed 2024-05-08 | $28.54M derived: sum of 2 quarters · filed 2024-05-08 | $40.92M derived: sum of 3 quarters · filed 2024-05-08 | $54.88M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $14.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $26.79M derived: sum of 2 quarters · filed 2024-02-28 | $40.75M derived: sum of 3 quarters · filed 2024-02-28 | $51.70M 10-K · filed 2024-02-28 |
| 2022-09-30 | $12.38M 10-Q · filed 2023-11-07 | $26.34M derived: sum of 2 quarters · filed 2023-11-07 | $37.29M 10-Q · filed 2023-11-07 | $49.97M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $13.96M 10-Q · filed 2023-08-08 | $24.91M 10-Q · filed 2023-08-08 | $37.59M derived: sum of 3 quarters · filed 2024-02-28 | $51.79M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $10.95M 10-Q · filed 2023-05-03 | $23.64M derived: sum of 2 quarters · filed 2024-02-28 | $37.83M derived: sum of 3 quarters · filed 2024-02-28 | $51.33M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $12.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $26.88M derived: sum of 2 quarters · filed 2024-02-28 | $40.38M derived: sum of 3 quarters · filed 2024-02-28 | $53.84M 10-K · filed 2024-02-28 |
| 2021-09-30 | $14.20M 10-Q · filed 2022-11-02 | $27.70M derived: sum of 2 quarters · filed 2022-11-02 | $41.15M 10-Q · filed 2022-11-02 | $55.26M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $13.50M 10-Q · filed 2022-08-03 | $26.96M 10-Q · filed 2022-08-03 | $41.06M derived: sum of 3 quarters · filed 2023-02-23 | $55.55M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $13.45M 10-Q · filed 2022-05-04 | $27.56M derived: sum of 2 quarters · filed 2023-02-23 | $42.04M derived: sum of 3 quarters · filed 2023-02-23 | $56.87M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $14.11M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $28.59M derived: sum of 2 quarters · filed 2023-02-23 | $43.41M derived: sum of 3 quarters · filed 2023-02-23 | $58.53M 10-K · filed 2023-02-23 |
| 2020-09-30 | $14.48M 10-Q · filed 2021-11-04 | $29.31M derived: sum of 2 quarters · filed 2021-11-04 | $44.43M 10-Q · filed 2021-11-04 | $56.02M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $14.82M 10-Q · filed 2021-08-04 | $29.95M 10-Q · filed 2021-08-04 | $41.53M derived: sum of 3 quarters · filed 2022-02-24 | $53.06M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $15.12M 10-Q · filed 2021-05-05 | $26.71M derived: sum of 2 quarters · filed 2022-02-24 | $38.23M derived: sum of 3 quarters · filed 2022-02-24 | $48.16M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $11.59M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $23.11M derived: sum of 2 quarters · filed 2022-02-24 | $33.04M derived: sum of 3 quarters · filed 2022-02-24 | $43.13M 10-K · filed 2022-02-24 |
| 2019-09-30 | $11.52M 10-Q · filed 2020-11-05 | $21.45M derived: sum of 2 quarters · filed 2020-11-05 | $31.54M 10-Q · filed 2020-11-05 | $39.87M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $9.92M 10-Q · filed 2020-08-06 | $20.01M 10-Q · filed 2020-08-06 | $28.34M derived: sum of 3 quarters · filed 2021-02-25 | $35.52M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $10.09M 10-Q · filed 2020-05-07 | $18.42M derived: sum of 2 quarters · filed 2021-02-25 | $25.59M derived: sum of 3 quarters · filed 2021-02-25 | $32.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $8.33M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $15.50M derived: sum of 2 quarters · filed 2021-02-25 | $21.90M derived: sum of 3 quarters · filed 2021-02-25 | $25.97M 10-K · filed 2021-02-25 |
| 2018-09-30 | $7.17M 10-Q · filed 2019-11-13 | $13.58M derived: sum of 2 quarters · filed 2019-11-13 | $17.64M 10-Q · filed 2019-11-13 | |
| 2018-06-30 | $6.40M 10-Q · filed 2019-08-13 | $10.47M 10-Q · filed 2019-08-13 | ||
| 2017-12-31 | $11.74M 10-K · filed 2020-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |